Effects of the glycoprotein IIb/IIIa antagonist Roxifiban on P-selectin expression, fibrinogen binding, and microaggregate formation in a phase I dose-finding study: no evidence for platelet activation during treatment with a glycoprotein IIb/IIIa antagonist

Author： Seiffert Dietmar   Thomas Beth E.   Bradley Jodi D.   Munzer Deborah A.   Tchinnes Maureen A.   Kornhauser David M.   Cain Valerie A.   Hua Tsuhung A.   Feuerstein Giora Z.   Martin David E.   Stern Andrew M.  

Publisher： Informa Healthcare

ISSN： 1369-1635

Source： Platelets, Vol.14, Iss.3, 2003-05, pp. : 179-187

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Differences between Activation Thresholds for Platelet P-Selectin and Glycoprotein IIb-IIIa Expression and Their Clinical Implications

By Holmes M.B.   Sobel B.E.   Howard D.B.   Schneider D.J.  

Thrombosis Research, Vol. 95, Iss. 2, 1999-07 ,pp. : 75-82

Elsevier

Access to resources Recommend Favorite

Effects of platelet glycoprotein IIb-IIIa number and glycoprotein IIIa Leu33Pro polymorphism on platelet aggregation and sensitivity to glycoprotein IIb-IIIa antagonists

By Sirotkina Olga   Khaspekova Svetlana   Zabotina Anna   Shimanova Yulia   Mazurov Alexey  

Platelets, Vol. 18, Iss. 7, 2007-11 ,pp. : 506-514

Informa Healthcare

Access to resources Recommend Favorite

Use of glycoprotein IIb/IIIa receptor antagonist in prosthetic valve thrombosis

By Caceres-Loriga F.   Santos-Gracia J.  

Platelets, Vol. 21, Iss. 7, 2010-11 ,pp. : 583-583

Informa Healthcare

Access to resources Recommend Favorite

The IN VITRO AND IN VIVO PHARMACOLOGICAL PROFILES OF A PLATELET GLYCOPROTEIN IIb/IIIa ANTAGONIST, NSL-9403

By Katada J.   Takiguchi Y.   Muramatsu M.   Fujiyoshi T.   Uno I.  

Thrombosis Research, Vol. 88, Iss. 1, 1997-10 ,pp. : 27-40

Elsevier

Access to resources Recommend Favorite

The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary

By  

Current Cardiology Reviews, Vol. 4, Iss. 4, 2008-11 ,pp. : 293-299

Bentham Science Publishers

Access to resources Recommend Favorite